NASDAQ:CLNN
Clene Inc. Stock News
$0.316
-0.0131 (-3.98%)
At Close: Jun 03, 2024
Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)
07:30am, Tuesday, 28'th May 2024
SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharm
Clene to Present at Upcoming May Conferences
08:00am, Tuesday, 14'th May 2024
SALT LAKE CITY, May 14, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage bio
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
09:56am, Wednesday, 08'th May 2024
Clene Inc. (CLNN) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.15 per share a year ago.
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
08:00am, Wednesday, 08'th May 2024
SALT LAKE CITY, May 08, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinical-stage bi
3 Speculative Penny Stocks Offering High-Upside Potential for Under a Buck
06:00am, Wednesday, 08'th May 2024
There are speculative ideas and then there are penny stocks under $1. Outside of forex trading or high-risk options trades, it generally doesn't get much more treacherous than this space.
SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage bioph
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
02:19pm, Tuesday, 26'th Mar 2024
When it comes to deciding whether you should acquire penny stocks or not, the answer is no. Okay, so we're done here, right?
SALT LAKE CITY, March 15, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopha
Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates
10:31am, Wednesday, 13'th Mar 2024
Clene Inc. (CLNN) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.16 per share a year ago.
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
08:00am, Wednesday, 13'th Mar 2024
SALT LAKE CITY, March 13, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopha
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
08:00am, Thursday, 29'th Feb 2024
SALT LAKE CITY, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biophar
7 Underappreciated Penny Stocks That Pack a Wallop
05:02pm, Monday, 12'th Feb 2024
Let's be brutally honest with each other – underappreciated penny stocks are that way for a reason. I'm not going to say they stink but they're incredibly unpredictable.
Clene says FDA finds ALS drug data not enough for accelerated nod
11:25am, Thursday, 21'st Dec 2023
Dec 21 (Reuters) - Clene (CLNN.O) said on Thursday data on its therapy to treat a type of neurological disease did not meet the U.S. drug regulator's target for accelerated approval.
Clene Provides Update on ALS Clinical Development Meeting With FDA
07:00am, Thursday, 21'st Dec 2023
SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biophar
SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biophar